Group 1 - The core point of the article is that 石四药集团 (Shijiazhuang Pharmaceutical Group) has seen a significant stock price increase of nearly 14% following the announcement of obtaining production registration approvals for two pharmaceutical products from the National Medical Products Administration of China [1] - The company has received production registration approvals for 乌拉地尔缓释胶囊 (Urapidil Sustained-release Capsules, 30mg) and 盐酸尼卡地平氯化钠注射液 (Nicardipine Hydrochloride Sodium Injection, 200ml), both classified as Category 3 chemical drugs, marking them as the first domestic company to receive such approvals [1] - Additionally, the company has obtained production registration approval for 盐酸屈他维林注射液 (Sufentanil Hydrochloride Injection, 2ml), classified as a Category 4 chemical drug, also indicating successful consistency evaluation [1] Group 2 - Citigroup's research report indicates that in the 11th round of drug procurement, 石四药集团 has 11 drugs, including Bromhexine, which is expected to account for approximately 1.5% of projected sales in 2024 [1] - The report suggests that the company has a strong chance of winning contracts for peritoneal dialysis solutions and renewing contracts for other products [1] - Citigroup views 石四药集团 as a winner among generic drug companies and the largest beneficiary of drug procurement policies [1]
石四药集团午后涨近14% 旗下三种新药获批生产注册批件 花旗称公司受益药品集采